The Sage Group

What The Sage Group does

The Sage Group is a privately held, specialist transaction advisory firm serving the global healthcare and life sciences sector. Founded in 1994 and headquartered between the United States (Clinton, New Jersey) and the United Kingdom (Newmarket), the firm assists biotech, pharmaceutical, and health-technology companies with licensing, partnering, and strategic M&A transactions, alongside adjacent offerings in non-dilutive financing sourcing, business development, and value modeling. Its service portfolio is delivered through three named client tracks: biotech and MedTech companies seeking to commercialize assets or exit, pharmaceutical and strategic buyers pursuing acquisition of innovation, and investors and owners pursuing structured sale or recapitalization. The firm reports a cumulative track record of more than 250 completed transactions for over 300 clients, representing more than $7 billion in transaction value across the United States, Europe, Japan, China, Australia, the Middle East, and Latin America.

The firm's core technology is SAGEIQ, a proprietary AI-enabled global intelligence platform used internally to identify, qualify, and close licensing, partnering, and M&A transactions. SAGEIQ is described as combining knowledge retrieval and predictive analytics to support buyer identification, data-backed asset positioning, and disciplined outreach; however, it is positioned as an enabling layer rather than a standalone product. Deal execution is carried out by senior principals and Executive Directors who are former Founders, Chairmen, Presidents, CEOs, and COOs of healthcare companies, with senior hires in 2020 (Dr. Christine T. Fischette from Novartis/Pfizer/Roche and Dr. Clarissa Ceruti from Bioindustry Park/Abcam) reinforcing bench depth. Affiliate relationships extend the offering with regulatory advice across the US, Europe, and APAC, and pricing/market access assessments in the US and Europe.

The Sage Group generates revenue through professional advisory fees on a quote-based engagement structure, typical of M&A and licensing advisory mandates, including engagement fees, success fees upon transaction completion, and ongoing advisory retainers. The firm operates a sales-led go-to-market, with no standalone software product, no public listing, and no disclosed external funding; ownership appears founder-led (Wayne Pambianchi as Founder, Executive Director, and Lead US Partner; Dr. Bill Mason as Executive Director and Lead Partner for Europe). Customer acquisition is driven by senior-principal direct relationships, industry conferences such as BIO-Europe, professional referrals, and content marketing through case studies and transaction announcements.

Name

The Sage Group

Legal name

Sage Healthcare Limited

Website

https://sagehealthcare.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Sage Group is a privately held, specialist transaction advisory firm founded in 1994 that helps biotech, pharmaceutical, and health-technology companies execute licensing, partnering, and strategic M&A transactions globally, powered by its proprietary SAGEIQ AI intelligence platform and delivered through senior principals across North America, Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Healthcare and Life Sciences Transaction Advisory

NAICS

Management Consulting Services (54161), Management, Scientific, and Technical Consulting Services (5416)

SIC

Services-Management Consulting Services (8742), Investment Advice (6282)

akta.pro primary industry

M&A Advisory (Buy-Side & Sell-Side) (BPAHAOAA)

akta.pro secondary industries

Sell-Side M&A Advisory (FSAEAGAA), Buy-Side M&A Advisory (FSAEAGAB), Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG), Strategic Partnerships, Alliances & JVs Advisory (BPAHADAI)

Keywords

• Transaction advisory services
• Healthcare M&A advisory
• Biotech licensing advisory
• Pharma deal advisory
• Life sciences consulting

Headquarters

HQ city

Clinton

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Transaction Advisory Services: Professional advisory fees for licensing, partnering and M&A transaction services. Revenue generated through engagement fees, success fees upon transaction completion, and ongoing advisory retainer arrangements with clients in the life sciences sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

The Sage Group provides strategic transaction advisory services to healthcare and life sciences companies, helping biotech, pharma, and health-technology clients license, partner, and complete strategic M&A worldwide. Services span buyside and sellside licensing, mergers and acquisitions, asset and IP divestments, acquisition searches, sourcing of non-dilutive financing, business development, corporate partnering, and value modelling, all delivered through senior principals supported by the proprietary SAGEIQ AI-enabled global intelligence platform.

Product overview

The Sage Group operates as a specialist transaction advisory firm serving the bioscience sector, combining 30+ years of senior dealmaking experience with SAGEIQ, its proprietary AI-enabled global intelligence platform. The firm does not offer standalone software products; instead, its core offering is transaction advisory services—assisting life science companies with licensing, partnering, and M&A transactions. SAGEIQ powers the firm's intelligence capabilities to identify strategic buyers, create data-backed positioning, and build competitive tension around transactions. Services span the full deal lifecycle from strategic assessment through deal execution, with affiliate offerings in regulatory strategy and pricing/reimbursement assessment.

Differentiator

Problem solved

Functional benefit

Products and services

• Transaction Advisory Services Strategic transaction advisory services for biotech, pharma, and health-technology clients, including buyside and sellside licensing for products and technologies, mergers and acquisitions, asset and IP divestments, acquisition searches, sourcing of non-dilutive financing from strategic partners, business development, corporate partnering, and value modelling. Services are delivered through senior principals supported by the proprietary SAGEIQ AI-enabled global intelligence platform and span assets from preclinical to early clinical stage through to global commercial products.

Quantifiable outcome

• 300+ multinational transactions completed across US, Europe, Japan, China, Australia, Middle East and Latin America
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Locust Walk: Healthcare and life-sciences focused transaction advisory firm that supports biotech and medtech companies with strategic transactions, licensing and partnering deals—directly comparable in services, client base and business model.
• Torreya Partners: Healthcare-focused M&A and capital markets advisory serving pharma, biotech and specialty pharma companies. Highly comparable in life-sciences specialization and global deal execution.
• MTS Health Partners: boutique investment bank exclusively focused on healthcare M&A, providing sell-side and strategic advisory to middle-market healthcare companies—directly comparable in deal focus and clientele.
• Outcome Capital: Life sciences advisory firm providing M&A, licensing and strategic partnering services to emerging and established life sciences companies—highly comparable in service mix and client segment.
• Back Bay Life Science Advisors: Boston-based life sciences advisory firm focused on capital raising, strategic partnering, and M&A for biopharma and medtech companies—directly comparable boutique peer.
• PharmaVentures: Global transaction advisory firm focused exclusively on the pharma and biotech sector, providing M&A, licensing and strategic alliance services—directly comparable in deal type and client base.

Broad incumbents

• Jefferies Healthcare Group: Large investment bank with a dedicated global healthcare franchise offering M&A, licensing and capital markets services to biotech and pharma—competes for many of the same life-sciences mandates at greater scale.
• Lazard Healthcare: Global investment bank with a dedicated Healthcare and Life Sciences practice providing strategic M&A and capital advice to pharma, biotech and medtech clients—an established competitor with broader capabilities.
• Piper Sandler Healthcare: Diversified middle-market investment bank with a healthcare group serving biotech, pharma and medtech companies with M&A, licensing and equity capital markets services.

Emerging players

• DealForma: AI-driven deal sourcing and biopharma transaction data platform that complements or competes with traditional advisory sourcing workflows—an emerging, tech-enabled counterpoint to SAGEIQ.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/wix
• YouTubeyoutube.com/user/Wix
• Facebookfacebook.com/wix
• LinkedInlinkedin.com/company/the-sage-group-inc
• Instagraminstagram.com/wix
• TikToktiktok.com/@wix

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Sage Group